DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Phase 3 Study - Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

Information source: Paratek Pharmaceuticals Inc
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Skin Structures and Soft Tissue Infections

Intervention: PTK 0796 (Drug); Linezolid (Drug)

Phase: Phase 3

Status: Withdrawn

Sponsored by: Paratek Pharmaceuticals Inc

Official(s) and/or principal investigator(s):
Robert Arbeit, MD, Study Director, Affiliation: Paratek Pharmaceuticals Inc

Summary

A Phase III trial to demonstrate the safety and efficacy of PTK 0796 in the treatment of complicated skin and skin structure infections (cSSSI).

Clinical Details

Official title: A Randomized, Evaluator-Blinded, Phase 3 Study to Compare the Safety and Efficacy of PTK 0796 With Linezolid in the Treatment of Adults With Complicated Skin and Skin Structure Infection

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Clinical success at follow-up

Secondary outcome: To evaluate safety of dosing regimens

Detailed description: The pharmacologic profile of PTK 0796 in humans suggests that it has the potential to be used safely and effectively for this indication. Data from in vitro and animal studies support this hypothesis. In PTK 0796-CSSI-0805 the safety and efficacy of PTK 0796 in the treatment of cSSSI will be compared to an antibiotic approved for this indication by the FDA. Initial treatment will be administered intravenously with the option for subsequent oral treatment.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Has and acute complicated skin and skin structure infection with findings of systemic

inflammatory response

- Patients, ages 18 years or older

- Is expected to require greater than or equal to 4 days antibiotic therapy

- Female patients must not be pregnant at the time of enrollment and must agree to a

reliable method of birth control during the study and for 30 days following the last dose of study drug Exclusion Criteria:

- Has received an investigational drug within the past 1 month

- Has been previously enrolled in this protocol

- Has received >48hr of potentially effective systemic antibiotic immediately prior to

study drug

- Is nursing

Locations and Contacts

Additional Information

Starting date: July 2009
Last updated: May 8, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017